scholarly journals Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug self-administration in monkeys

2014 ◽  
Vol 231 (14) ◽  
pp. 2751-2758 ◽  
Author(s):  
Kevin B. Freeman ◽  
Jennifer E. Naylor ◽  
Thomas E. Prisinzano ◽  
William L. Woolverton
Keyword(s):  
Salvinorin A ◽  
Self Administration ◽  
Opioid Agonist ◽  
Kappa Opioid ◽  
Kappa Opioid Agonist

scholarly journals Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability

2017 ◽  
Vol 60 (9) ◽  
pp. 3866-3878 ◽  
Author(s):  
Alexander M. Sherwood ◽  
Rachel Saylor Crowley ◽  
Kelly F. Paton ◽  
Andrew Biggerstaff ◽  
Benjamin Neuenswander ◽  
...  
Keyword(s):  
Metabolic Stability ◽  
Salvinorin A ◽  
Structural Flexibility ◽  
Opioid Agonist ◽  
Kappa Opioid ◽  
Kappa Opioid Agonist

scholarly journals Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum

2011 ◽  
Vol 115 (1-2) ◽  
pp. 150-155 ◽  
Author(s):  
Matthew W. Johnson ◽  
Katherine A. MacLean ◽  
Chad J. Reissig ◽  
Thomas E. Prisinzano ◽  
Roland R. Griffiths
Keyword(s):  
Salvia Divinorum ◽  
Salvinorin A ◽  
Opioid Agonist ◽  
Kappa Opioid ◽  
Dose Effects ◽  
Kappa Opioid Agonist ◽  
Human Psychopharmacology

scholarly journals Human Psychopharmacology and Dose-Effects of Salvinorin A, a Kappa-Opioid Agonist Hallucinogen Present in the Plant Salvia Divinorum

2011 ◽  
Author(s):  
Matthew W. Johnson ◽  
Katherine A. Maclean ◽  
Chad R. Reissig ◽  
Thomas P. Prisinzano ◽  
Roland R. Griffiths
Keyword(s):  
Salvia Divinorum ◽  
Salvinorin A ◽  
Opioid Agonist ◽  
Kappa Opioid ◽  
Dose Effects ◽  
Kappa Opioid Agonist ◽  
Human Psychopharmacology

kappa-Opioid agonist inhibition of osmotically induced AVP release: preferential action at hypothalamic sites

1996 ◽  
Vol 270 (2) ◽  
pp. E367-E372 ◽  
Author(s):  
N. F. Rossi ◽  
D. P. Brooks
Keyword(s):  
Potent Inhibitor ◽  
Opiate Receptors ◽  
Opioid Antagonist ◽  
Posterior Pituitary ◽  
Opioid Agonist ◽  
Kappa Opioid ◽  
Water Diuresis ◽  
Kappa Agonist ◽  
Opioid Agonists ◽  
Kappa Opioid Agonist

Although several studies indicate that kappa-opioid agonists induce a water diuresis by inhibiting vasopressin (AVP) secretion, the locus of the kappa-receptors (neurohypophysial vs. hypothalamic) responsible for this effect remains unclear. We have ascertained the effect of the selective kappa-agonist BRL-52656 (BRL) on AVP secretion by using compartmentalized rat hypothalamoneurohypophysial explants in culture. When applied to the hypothalamus, nanomolar concentrations of BRL inhibited osmotically stimulated AVP secretion. This response was blocked by the highly selective kappa-opioid antagonist nor-binaltorphimine (BNI). However, osmotically stimulated AVP release was suppressed at the neurohypophysial site only by 100 nM BRL and was not reversed by BNI but only by naloxone. This dose of BRL, administered to the posterior pituitary compartment, did not appear to act by the agonist gaining access to hypothalamic kappa-opiate receptors, because BNI added to the hypothalamus failed to prevent the inhibition of AVP secretion. The data demonstrate that BRL is a potent inhibitor of osmotically stimulated AVP secretion via activation of kappa-opiate receptors within the hypothalamus, but that higher concentrations of the drug may also stimulate non-kappa-neurohypophysial opiate receptors that suppress AVP release.

Sign in / Sign up

Export Citation Format

Share Document